We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 109

Ambry Genetics countersues Myriad Genetics in genetic patent infringement suit
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

Responding to the patent infringement claims asserted against it by Myriad Genetics, Ambry Genetics Corp. denies that the 15 patents at issue were


Do DNA patents affect genetic sequencing and testing advances?
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

University of Missouri-Kansas City School of Law Professor Christopher Holman writes in the most recent issue of Nature Technology that while DNA sequencing technology has spawned a myriad of patent-related lawsuits, “aggressive patent acquisition and enforcement practices” show no signs of abating and may not necessarily be hindering the development of next-generation DNA sequencing and analysis technologies


U.S. Supreme Court issues ruling on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Supreme Court has determined that while human genes and the information they encode are not patent eligible, despite the effort required to


CRS issues overview of IP issues for gene-related discoveries
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

The Congressional Research Service (CRS) recently released a report titled "Gene Patents: A Brief Overview of Intellectual Property Issues." The


Indian pharma interests challenge U.S. allegations of discriminatory treatment
  • Shook Hardy & Bacon LLP
  • India, USA
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • April 3 2014

The U.S. Food and Drug Administration (FDA) announces the availability of draft Guidance for Industry titled "Labeling for Human Prescription Drug


Pharma trade group seeks biologics data exclusivity for international trade
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

PhRMA has reportedly called for the U.S. Trade Representative to go outside provisions in the Korea-U.S. trade deal (KORUS) and press for a 12-year period of exclusivity for biologics in ongoing Trans-Pacific Partnerships (TPP) negotiations


Is FTC considering fast-track rulemaking to stop “pay-for-delay” drug deals?
  • Shook Hardy & Bacon LLP
  • USA
  • June 16 2011

According to a news source, the Federal Trade Commission (FTC) may be planning to adopt a rule under expedited procedures to block patent settlements, known as “pay-for-delay” deals, between name-brand drug manufacturers and generic drug makers


Violations of discovery orders result in default judgment, monetary sanctions, potential discipline
  • Shook Hardy & Bacon LLP
  • USA
  • August 18 2011

A federal court in Texas has imposed severe sanctions in a patent infringement lawsuit, due to repeated violations of its discovery orders and the creation of a fraudulent discovery-related document; a default judgment has been entered against the violator, and information about the document has been forwarded to alert the district’s chief judge “of the need to potentially take disciplinary measures” against counsel


Medical treatment claims deemed patentable on reconsideration after Bilski
  • Shook Hardy & Bacon LLP
  • USA
  • January 13 2011

The Federal Circuit Court of Appeals has confirmed its earlier decision, rendered before Bilski v. Kappos, 130 S. Ct. 3218 (2010), was decided, and ruled that methods for determining the optimal dosage of thiopurine drugs used to treat gastrointestinal and non-gastrointestinal autoimmune diseases recite patentable subject matter under 101